Cadrenal Therapeutics CEO Quang Pham Sells Shares

Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD), executed a planned sale of 9,029 shares on June 26, 2026. The shares were sold at an average price of $3.05, totaling approximately $27,538. This transaction was part of a pre-arranged trading plan.

Insider Buying and Selling at Cadrenal Therapeutics, Inc.

Pham's recent sale was part of a series of planned transactions. On June 25, 2026, he sold 2,127 shares at $3.00, and earlier, on June 23, he sold 2,277 shares at $3.20. These sales follow others on June 22 and June 16, all conducted under Rule 10b5-1 plans.

Other Institutional Activity in Cadrenal Therapeutics

Vanguard Capital Management LLC opened a new position in Cadrenal Therapeutics with 45,201 shares valued at $231,429. Geode Capital Management, LLC increased its stake by 7,098 shares, ending with 21,626 shares worth about $110,724, marking a 48.9% increase. BlackRock, Inc. also grew its holdings by 1,974 shares to a total of 5,496 shares valued at $28,140, reflecting a 56% increase.

Cadrenal Therapeutics, Inc. Stock Up 98.1%

Shares of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD) traded near $3.05 on Saturday. The company has a market capitalization of approximately $8.8 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock's 52-week range is between $2.55 and $14.64, with a 50-day moving average of $4.84 and a 200-day moving average of $8.25. Cadrenal's beta is 1.613, indicating higher volatility compared to the broader market.

Analysts Set New Price Targets

On April 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on Cadrenal Therapeutics, setting a price target of $13. The stock has a consensus rating of 'strong buy' with an average target price of $27.67, based on three analyst opinions.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing therapies for serious immune and thrombotic conditions. The company is advancing Tecarfarin, an oral anticoagulant in Phase 3 trials, and CAD-1005, a treatment for heparin-induced thrombocytopenia, which has completed Phase 2 trials. Cadrenal also collaborates with Abbott Global Enterprises Limited to evaluate Tecarfarin's efficacy and safety.

Bottom Line

Quang Pham's planned share sales are part of his role as CEO and are not uncommon for executives. Investors keep an eye on insider transactions for potential insights into company management's view of the business. Cadrenal Therapeutics remains a volatile stock, with significant institutional interest and strong analyst ratings. As always, 13F filings and insider trades are backward-looking and may not reflect the current state of holdings.